Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard Post History

by CancerSlayer


V.TLT

RE:New List of Competition from UroToday

Eoganacht wrote: This recent article from UroToday (01 April) reveals that...

April 2, 2022

V.TLT

RE:See you all…

My post mysteriously reappeared lol...or more likely I'm just getting old...

March 30, 2022

V.TLT

See you all…

...at the finish line or under the Vegas neon : ).  The next news...

March 30, 2022

V.TLT

RE:1y ago: The launch of the Anti-Cancer Therapy Research

Well said...re: your following comment: "TLT's technology has the...

March 29, 2022

V.TLT

RE:RE:RE:66% the number to beat...

Eoganacht wrote: I agree that "the threshold for approval is likely...

March 27, 2022

V.TLT

RE:66% the number to beat...

Based on the data thus far from optimized patients, it certainly looks like a...

March 27, 2022

V.TLT

RE:$TLTFF THAT NASTY A$$ HONEYBADGER!

Float...I think that narrator lost his job at NAT GEO lol.

March 24, 2022

V.TLT

RE:RE:Lets not fool ourselves................

2000%.  Is that all?

March 22, 2022

V.TLT

RE:RE:RE:RE:The FDA might have no choice...

Eoganacht wrote: "Hi wildbird1 - If TLD1433 is approved...

March 22, 2022

C.COOL

RE:Gearing up

Need to see pen to paper followed by actual scaling up of production...

March 19, 2022

V.TLT

RE:RE:RE:RE:RE:RE:On Breakthrough designation, ImmunityBio went for 1.4$ to 7$

CancerSlayer wrote:   ScienceFirst wrote: Take two, as there are...

March 17, 2022

V.TLT

RE:RE:RE:RE:RE:On Breakthrough designation, ImmunityBio went for 1.4$ to 7$

ScienceFirst wrote: Take two, as there are too many typos" By doing a...

March 17, 2022

V.TLT

RE:Dr Sherri's statement of "Virtually No Side Effects"

skys1 wrote: isn't as yet priced into the stock, IMO. The side effects of...

March 17, 2022

V.TLT

RE:RE:RE:RE:RE:« interim analysis » and « successfully treated »

Long day in the trenches.  So sorry for your loss oilmimer....my prayers...

March 17, 2022

V.TLT

RE:RE:« interim analysis » and « successfully treated »

skys1 wrote: ScienceFirst, That is a great description of what our position...

March 15, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Treated Patients 13 to 30

langosta wrote: If next week we get a good solid update I don't mind...

March 12, 2022

V.TLT

RE:RE:RE:RE:RE:Treated Patients 13 to 30

I welcome any newsletter delay....suggests they may be awaiting/compiling...

March 10, 2022

V.TLT

RE:RE:RE:RE:Treated Patients 13 to 30

DJDawg wrote: Great conversation everyone. I just wanted to say that the...

March 10, 2022

V.TLT

RE:RE:RE:Float, let's wait for the data now.

Well said SF....like the informative posts.  I agree about the...

March 10, 2022

V.TLT

RE:RE:RE:RE:Reading the tea leaves...

Never liked the idea of a quarterly newsletter...prefer they just report...

March 8, 2022